Genitourinary Radiology: Page 33

Biomarker test could direct MRI use for prostate cancer

By Wayne Forrest

Dutch researchers are reporting promising results using a new urinary biomarker risk-scoring system to test for the possibility of prostate cancer. The test could be used to select which patients should be sent on for additional MRI scans or biopsy, according to a study published in the October issue of The Prostate.

October 12, 2017

AI gives one-stop shopping for urinary stone evaluation

By Erik L. Ridley

An artificial intelligence (AI) algorithm can accurately detect and classify urinary stones based solely on images from noncontrast single-energy CT scans, according to research presented at last week's Society for Imaging Informatics in Medicine's Conference on Machine Intelligence in Medical Imaging.

October 4, 2017

Accuray touts CyberKnife clinical results

By AuntMinnie.com staff writers

Radiation oncology firm Accuray is highlighting data from a study that showed 98.4% of men with low-risk prostate cancer who underwent stereotactic body radiation therapy (SBRT) with the company's CyberKnife system had local disease control 10 years later.

September 25, 2017

BMJ: Multiparametric MRI has role in prostate screening

By AuntMinnie.com staff writers

Thanks to recent research demonstrating its high sensitivity and negative predictive value for clinically significant prostate cancers, multiparametric MRI (MP-MRI) shows potential as a screening triage tool for identifying these all-important cases, according to a new editorial published in BMJ.

September 19, 2017

MRI elastograms better than biopsy to assess kidney scarring

By Wayne Forrest

Researchers from Canada have discovered that MRI measurements of stiffness in patients who received kidney transplants can gauge damage to the organ and predict future kidney function within one year, according to a study published online August 30 in the Clinical Journal of the American Society of Nephrology.

August 30, 2017

New PET tracer could work well for prostate cancer

By Brian Casey

A new PET radiopharmaceutical based on carbon-11-labeled sarcosine could offer an alternative to choline-11-based PET for imaging patients with prostate cancer, according to a study published in the Journal of Nuclear Medicine.

August 6, 2017

IsoRay touts prostate cancer treatment data

By AuntMinnie.com staff writers

Medical isotope developer IsoRay is highlighting data that show that brachytherapy with the isotope cesium-131 is beneficial for prostate cancer patients -- and offers a less invasive and less costly treatment alternative to surgery or radiation treatment.

July 31, 2017

Luminal water MRI could be best for prostate cancer

By Wayne Forrest

Researchers from the University of British Columbia are reporting early success in developing a novel T2-based MRI technique that uses water content in prostate tissue to detect and grade cancer. The method outperformed several other MRI parameters, according to a study published in the August issue of Radiology.

July 30, 2017

Metal-free MRI contrast agent shows promise

By AuntMinnie.com staff writers

Researchers from the Massachusetts Institute of Technology and the University of Nebraska have developed a metal-free MRI contrast agent that could be safer for pediatric imaging and patients with kidney issues, according to a study published online July 12 in ACS Central Science.

July 16, 2017

PBS report targets price hike for V/Q radiotracers

By Wayne Forrest

Escalating costs for two radiopharmaceuticals used for ventilation/perfusion (V/Q) nuclear medicine scans in lung and kidney imaging are drawing the ire of pharmacies that prepare the materials for distribution to hospitals in the U.S., according to a June 30 report by PBS NewsHour.

June 29, 2017

SNMMI Image of the Year awarded to German researchers

By Wayne Forrest

DENVER - The Society of Nuclear Medicine and Molecular Imaging (SNMMI) on Wednesday awarded its Image of the Year to researchers who used PET/CT followed by fluorescence-guided surgery to demonstrate how dual-labeled prostate-specific membrane antigen (PSMA) inhibitors based on PSMA-11 enhance preoperative staging of metastatic prostate cancer.

June 14, 2017

SNMMI: PET/CT with prostate agent changes therapy plans

By AuntMinnie.com staff writers

Australian researchers found that treatment plans for more than half of prostate cancer patients were changed due to the results of PET/CT scans using a radiopharmaceutical that combines gallium-68 with a molecular compound that homes in on prostate-specific membrane antigen, according to a study presented at this week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting.

June 13, 2017

Previous Page

Page 33 of 93

Next Page